Tocilizumab versus anakinra in COVID-19: results from propensity score matching

BACKGROUND: Tocilizumab and anakinra are anti-interleukin drugs to treat severe coronavirus disease 2019 (COVID-19) refractory to corticosteroids. However, no studies compared the efficacy of tocilizumab versus anakinra to guide the choice of the therapy in clinical practice. We aimed to compare the...

Descripción completa

Detalles Bibliográficos
Autores principales: Arcani, Robin, Correard, Florian, Suchon, Pierre, Kaplanski, Gilles, Jean, Rodolphe, Cauchois, Raphael, Leprince, Marine, Arcani, Vincent, Seguier, Julie, De Sainte Marie, Benjamin, Andre, Baptiste, Koubi, Marie, Rossi, Pascal, Gayet, Stéphane, Gobin, Nirvina, Garrido, Victoria, Weiland, Joris, Jouve, Elisabeth, Couderc, Anne-Laure, Villani, Patrick, Daumas, Aurélie
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250610/
https://www.ncbi.nlm.nih.gov/pubmed/37304271
http://dx.doi.org/10.3389/fimmu.2023.1185716

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10250610/
https://www.ncbi.nlm.nih.gov/pubmed/37304271
http://dx.doi.org/10.3389/fimmu.2023.1185716

Ejemplares similares